Comparative in vitro activities of seven new β-lactams, alone and in combination with β-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 1, 2006, Pages 22-25

  Gupta, Varsha ^a   Datta, Priya ^a   Agnihotri, Nalini ^a   Chander, Jagdish ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

lactam; lactam lactamase inhibitor; Gram negative bacilli

Indexed keywords

BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFDINIR; CEFEPIME; CEFPIROME; CEPHALOSPORIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TIMENTIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CITROBACTER; COMPARATIVE STUDY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEPHALOSPORIN RESISTANCE; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS;

EID: 33745099300     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000100005     Document Type: Article

References (20)

1. Ram S., Gupta R., Gaheer M., Uppal S. Prevalence of multiple drug resistant organisms in an intensive care burn unit. Indian J Med Res 2000;111:118-20.
2. Gales A.C., Jones R.N., Tumidge J., et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns and molecular typing in the global SENTRY antimicrobial surveillance program 1997-1999. Clin Infect Dis 2001;32(suppl 2):s146-55.
3. Mahapatra A., Samal B., Pattnaik D., et al. Antimicrobial susceptibility pattern of clinical isolates of non- fermentative bacteria. Indian J Pathol Microbiol 2003;46(3):526-7.
4. Troillet N., Samore H.M. Carmeli Y. Imipenem resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094-8.
5. Lee N., Yuen K.Y., Kumana C.R. Clinical role of beta- lactam/ beta-lactamase inhibitor combinations. Drugs 2003;63(14):1511-24.
6. Wexler H.M., Finegold S.M. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988:32(3):403-6.
7. Kosmidis J. Ticarcillin and clavulanic acid in serious infections. J Antimicrob Chemother 1986;17:169-75.
8. Guay D.R. Cefdinir: an advanced generation, broad spectrum oral cephalosporin. Clin Ther 2002;24(2):473-89.
9. Biedenbach D.J., Lewis M. T., Jones R. N. In vitro evaluation of cefepime and other broad -spectrum beta- lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35(4):277-83.
10. Forbes B.A., Sahm D.F. Weissfeld A.S. Bailey and Scott's Diagnostic Microbiology. Mosby, Missouri, USA, 1998.
11. National Committee for Clinical Laboratory Standards for antimicrobial disk susceptibility tests: Approved standards 7th edition. Villanova, Pa, National committee for clinical laboratory standards. 2000, vol 20, no1, M2- A7.
12. Taneja N., Maharwal S., Sharma M. Imipenem resistance in non-fermenters causing nosocomial urinary tract infections. Ind J Med Sci 2003;57(4):294-9.
13. Johnson D. M., Biedenbach D.J., Jones R.N. In vitro evaluation of broad -spectrum beta-lactams in the Philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35(4); 291-7.
14. Van Eldere J. Multicenter surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003;51(2):347-52.
15. Chitnis S.V., Chitnis V., Sharma N., Chitnis D.S. Current status of drug resistance among Gram-negative bacilli isolated from admitted cases in a tertiary-care. J Assoc Physician India 2003;51:28-32.
16. Levin A.S. Multi-resistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8(3):144-53.
17. Kucutkates E., Kocazeybek B. High resistance rate against 15 different antibiotics in aerobic gram negative bacteria isolates of cardiology cardiac care unit patients. Ind J Med Microbiol 2002;20(4):208-10.
18. Jones R.N., Varnam D.J. Antimicrobial activity of broad-spectrum agents tested against Gram- negative bacilli resistant to ceftazidime: report from SENTRY antimicrobial surveillance program. (North America, 2001). Diagn Microbiol Infect Dis 2002;44(4):379-82.
19. Sader H.S., Fritsche T.R., Mutnick A.H. Jones R.N. Contemporary evaluation of the in-vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn Microbiol Infect Dis 2003;47(3):515-25.
20. Watanabe N. Hiruma R., Katsu K. Comparative in vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem - resistant Pseudomonas aeruginosa. J. Antimicrob Chemother 1992;30(5):633-41.